In patients with at least 1-year posttreatment GH and IGF-1 follow-up, the disease-controlled rate (45.5% vs. 45.9%) was similar between patients with cancer in any period (n = 88) or without cancers (n = 1147) (Table 1). The gene discussed is GH1; the disease is cancer.